The Methodist Hospital Cornell University
Welcome,         Profile    Billing    Logout  
 3 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Iyer, Swaminathan
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
Europe, US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen Inc.
Peripheral T-cell Lymphoma
05/24
12/25
IMAGINE, NCT05138458: A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL

Suspended
1/2
40
US
MT-101, MT-101 + Conditioning (Lymphodepleting) Chemotherapy
Myeloid Therapeutics
Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides, Adoptive Cellular Immunotherapy, Cell Therapy
11/24
10/25
NCT06492304: A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies

Recruiting
1/2
290
US
CTX131
CRISPR Therapeutics
T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia
05/30
11/30
NCT05321147: Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

Completed
1
20
US, RoW
lacutamab, IPH4102
Innate Pharma
Peripheral T Cell Lymphoma
11/23
02/24

Download Options